Bottom line
AOD-9604 + Tesamorelin is marketed by one seller as "BURN 24" and appears as a component pairing in other listings. Clinics also use broader "Fat Burner" labels for materially different mixtures that add MOTS-c and/or Ipamorelin. No published study of the exact two-component or wider marketed formulations was identified.
No established or recommended human dose. Reported amounts below are market observations, not guidance.
Name and formulation variability
| Observed source/date | Claimed components | Claimed amounts | Verification limits |
|---|---|---|---|
| Genetic Peptide, "BURN 24" (2026) | AOD-9604, Tesamorelin | 3 / 10 mg | Single-vendor name; identity and contents not independently verified |
| Elite Health HRT, "Fat Burner" variant (2026) | AOD-9604, Tesamorelin, MOTS-c | Amounts not consistently published | Clinic-declared wider component set; not equivalent to BURN 24 |
| InShapeMD Texas, "Fat Burner" variant (2026) | AOD-9604, Tesamorelin, Ipamorelin, with or without MOTS-c | Amounts not consistently published | Clinic marketing name applied to a different three- or four-component set |
"BURN 24" is a single-vendor name. "Fat Burner" is a broad marketing category rather than a reproducible formulation and may include additional components.
Component evidence
| Component | Separate evidence | Evidence for combination | Compatibility/stability evidence |
|---|---|---|---|
| AOD-9604 | See component monograph | None identified for the two-component or wider variants | None identified |
| Tesamorelin | See component monograph; product-specific label evidence does not transfer to a mixture | None identified for the two-component or wider variants | None identified |
| MOTS-c | Present only in wider clinic variants; see monograph | None identified for the wider variants | None identified |
| Ipamorelin | Present only in wider clinic variants; see monograph | None identified for the wider variants | None identified |
Combination-specific studies
No published peer-reviewed study of BURN 24 or the cited "Fat Burner" component sets was identified. The names and claimed formulations are documented only as market observations.
Safety and interaction uncertainties
Two-, three-, and four-component products share adjacent marketing language but are not equivalent.
No combination-specific human safety, interaction, pharmacokinetic, or toxicology data were identified.
Product identity, purity, sterility, and co-formulation stability cannot be inferred from a listing.
A fixed multi-component product complicates attribution of unexpected effects.
Regulatory and product-quality notes
"BURN 24" and "Fat Burner" are marketing names, not regulatory or pharmacopoeial standards.
Tesamorelin's product-specific status does not extend to seller-created mixtures.
The cited vendor and clinic pages are low-quality evidence and do not establish efficacy, approval, or suitability for humans.
Evidence gaps
No combination-specific controlled study
No stable definition for the wider "Fat Burner" variants
No independent identity or content verification
No published compatibility or stability data
Sources
Genetic Peptide. BURN 24 market page. https://geneticpeptide.com/ accessed 2026-08-08.
Elite Health HRT. Fat Burner blend clinic page. https://elitehealthhrt.com/ accessed 2026-08-08.
InShapeMD Texas. Fat Burner blend clinic page. https://inshapemdtx.com/ accessed 2026-08-08.